Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss     Print Page | Close Window

SEC Filings

SC 13D
MEYER THOMAS filed this Form SC 13D on 04/03/2018
Entire Document
 
 

 

         
CUSIP No. H0381L104   13D   Page 3 of 6 Pages
         
         

Item 1.  Security and Issuer.

 

 This Schedule 13D relates to common shares, CHF 0.02 nominal value per share (the “Common Shares”) of Auris Medical Holding AG, a Swiss corporation (the “Issuer”). The principal executive offices of the Issuer are located at Bahnhofstrasse 21, 6300 Zug, Switzerland.

 

Item 2.  Identity and Background.

 

(a)This Statement is being filed on behalf of Thomas Meyer (the “Reporting Person”)

 

(b)The principal business address of the Reporting Person is Bahnhofstrasse 21, 6300 Zug, Switzerland

 

(c)The present occupation of the Reporting Person is Chairman and Chief Executive Officer of the Issuer. The Issuer’s principal business address is Bahnhofstrasse 21, 6300 Zug, Switzerland, and its principal business is the development of biopharmaceutical products for the treatment of inner ear disorders.

 

(d)The Reporting Person has not has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) in the past five years.

 

(e)The Reporting Persons has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

(f)The Reporting Person is a citizen of Switzerland.

 

Item 3.  Source or Amount of Funds or Other Consideration.

 

The Reporting Person acquired his Common Shares in exchange for common shares (the “Old Common Shares”) of the Issuer’s predecessor (“Old Auris”) pursuant to the Merger (as defined under Item 4 below).

 

The source of funds for the purchases of Old Auris’s securities was the personal funds of the Reporting Person.

 

The consideration for the purchase of the 72,350 Old Common Shares purchased pursuant to Stock Option Plan B (as described under Item 4 below) by the Reporting Person was CHF 231,520 (before fees and expenses). The consideration for the purchase of 6,000,000 Old Common Shares (5,999,750 of which were converted on a one-for-one basis to 5,999,750 Series A preferred shares) (as described under Item 4 below) was CHF 100,000 in 2003, CHF 2,014,000 in 2004 and CHF 700,000 in 2007. The consideration for the purchase of the Series B preferred shares (as described under Item 4 below) by the Reporting Person was CHF 400,000 on December 13, 2007, CHF 1,000,000 on February 25, 2011, CHF 168,480 on December 23, 2011 and CHF 320,000 on October 12, 2012 (before fees and expenses). The consideration for the purchase of the Old Common Shares in the IPO (as described under Item 4 below) by the Reporting Person was $480,000 (before fees and expenses). The consideration for the purchase of the Old Common Shares and warrants to purchase Old Common Shares in the 2017 Purchase (as described under Item 4 below) by the Reporting Person was $500,000 (before fees and expenses). The consideration for the purchase of the Old Common Shares in the 2018 Purchase (as described under Item 4 below) by the Reporting Person was $17,000 (before fees and expenses).

 

There was no consideration paid for Common Shares acquired in connection with the Merger.

 

The Reporting Person did not borrow any funds to effectuate the transaction whereby he received the securities that are the subject of this filing on Schedule 13D or any Old Common Shares. The Reporting Person used his personal funds to make the purchases described herein.